1. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Issue 4 (18th October 2018) Authors: Bleecker, Eugene R.; Wechsler, Michael E.; FitzGerald, J. Mark; Menzies-Gow, Andrew; Wu, Yanping; Hirsch, Ian; Goldman, Mitchell; Newbold, Paul; Zangrilli, James G. Journal: European respiratory journal Issue: Volume 52:Issue 4(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Issue 10056 (29th October 2016) Authors: FitzGerald, J Mark; Bleecker, Eugene R; Nair, Parameswaran; Korn, Stephanie; Ohta, Ken; Lommatzsch, Marek; Ferguson, Gary T; Busse, William W; Barker, Peter; Sproule, Stephanie; Gilmartin, Geoffrey; Werkström, Viktoria; Aurivillius, Magnus; Goldman, Mitchell Journal: Lancet Issue: Volume 388:Issue 10056(2016) Page Start: 2128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection. (9th April 2014) Authors: Osterholzer, Danielle A.; Goldman, Mitchell Editors: Saravolatz, Louis D. Journal: Clinical infectious diseases Issue: Volume 59:Number 2(2014:Jan. 15) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Issue 10056 (29th October 2016) Authors: Bleecker, Eugene R; FitzGerald, J Mark; Chanez, Pascal; Papi, Alberto; Weinstein, Steven F; Barker, Peter; Sproule, Stephanie; Gilmartin, Geoffrey; Aurivillius, Magnus; Werkström, Viktoria; Goldman, Mitchell Journal: Lancet Issue: Volume 388:Issue 10056(2016) Page Start: 2115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Issue 1 (January 2019) Authors: Busse, William W; Bleecker, Eugene R; FitzGerald, J Mark; Ferguson, Gary T; Barker, Peter; Sproule, Stephanie; Olsson, Richard F; Martin, Ubaldo J; Goldman, Mitchell Journal: Lancet Issue: Volume 7:Issue 1(2019) Page Start: 46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Overreliance on Standardized Protocols: A Pilot Study of Surgical Residents and Fellows. Issue 5 (May 2017) Authors: Terry, Paul D.; Knight, Margaret; Bollig, Reagan; Heidel, R. Eric; Miller, Preston; Quinn, Megan A.; Daley, Brian; Goldman, Mitchell Journal: American surgeon Issue: Volume 83:Issue 5(2017) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Issue 1 (January 2018) Authors: FitzGerald, J Mark; Bleecker, Eugene R; Menzies-Gow, Andrew; Zangrilli, James G; Hirsch, Ian; Metcalfe, Paul; Newbold, Paul; Goldman, Mitchell Journal: Lancet Issue: Volume 6:Issue 1(2018) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma. Issue 2 (22nd March 2019) Authors: Chia, Yen Lin; Yan, Li; Yu, Binbing; Wang, Bing; Barker, Peter; Goldman, Mitchell; Roskos, Lorin Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 2(2019) Page Start: 383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Issue 12 (December 2021) Authors: Schoser, Benedikt; Roberts, Mark; Byrne, Barry J; Sitaraman, Sheela; Jiang, Hai; Laforêt, Pascal; Toscano, Antonio; Castelli, Jeff; Díaz-Manera, Jordi; Goldman, Mitchell; van der Ploeg, Ans T; Bratkovic, Drago; Kuchipudi, Srilakshmi; Mozaffar, Tahseen; Kishnani, Priya S; Sebok, Agnes; Pestronk, A... Journal: Lancet neurology Issue: Volume 20:Issue 12(2021) Page Start: 1027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Successful Use of Hyperbaric Oxygen as Adjunctive Therapy for a Nonhealing Venous Ulcer in a Patient with Systemic Sclerosis and Pulmonary Arterial Hypertension: A Case Report and Review of the Literature. (24th February 2020) Authors: Biney, Isaac; Dudney, Tina; Goldman, Mitchell; Carder, Lee; Schriver, Elise Other Names: Terashima Takeshi Academic Editor. Journal: Case reports in pulmonology Issue: Volume 2020(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗